KEYNOTE‐024 prospectively randomized treatment‐naïve advanced NSCLC patients with PD‐L1 TPS ≥ 50% to either pembrolizumab (200 mg Q3W) or platinum‐doublet chemotherapy [17]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.